CO2022001218A2 - Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso - Google Patents
Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y usoInfo
- Publication number
- CO2022001218A2 CO2022001218A2 CONC2022/0001218A CO2022001218A CO2022001218A2 CO 2022001218 A2 CO2022001218 A2 CO 2022001218A2 CO 2022001218 A CO2022001218 A CO 2022001218A CO 2022001218 A2 CO2022001218 A2 CO 2022001218A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- pi4kiiiα
- preparation
- micromolecular inhibitor
- pharmaceutical composition
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000003937 drug carrier Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019094831 | 2019-07-05 | ||
| PCT/CN2020/100377 WO2021004422A1 (zh) | 2019-07-05 | 2020-07-06 | 小分子PI4KIIIα抑制剂组合物、其制备方法及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022001218A2 true CO2022001218A2 (es) | 2022-05-20 |
Family
ID=74115038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0001218A CO2022001218A2 (es) | 2019-07-05 | 2022-02-07 | Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230115711A1 (https=) |
| EP (1) | EP3995134A4 (https=) |
| JP (1) | JP2022538505A (https=) |
| KR (1) | KR20220071175A (https=) |
| CN (2) | CN118105372A (https=) |
| AU (1) | AU2020309681A1 (https=) |
| BR (1) | BR112022000155A2 (https=) |
| CA (1) | CA3149104A1 (https=) |
| CO (1) | CO2022001218A2 (https=) |
| IL (1) | IL289586A (https=) |
| MX (1) | MX2022000287A (https=) |
| PE (1) | PE20220942A1 (https=) |
| PH (1) | PH12022550254A1 (https=) |
| TW (1) | TW202126294A (https=) |
| WO (1) | WO2021004422A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114685566A (zh) * | 2020-12-31 | 2022-07-01 | 江苏挪贝肽医药科技有限公司 | 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法 |
| JP2024537837A (ja) * | 2021-09-30 | 2024-10-16 | ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド | ハロゲン化フェニルアルシンオキシド化合物およびその用途 |
| CN116478954B (zh) * | 2023-02-14 | 2025-06-10 | 中国农业大学 | 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002365110A1 (en) * | 2001-07-10 | 2003-07-15 | Massachusetts Institute Of Technology | Small molecule microarrays |
| EP2316943B1 (en) * | 2007-07-05 | 2013-06-19 | Novartis AG | DSRNA for treating viral infection |
| WO2016172952A1 (zh) * | 2015-04-30 | 2016-11-03 | 江苏挪贝肽医药科技有限公司 | PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用 |
| CN112437674A (zh) * | 2018-04-11 | 2021-03-02 | 新墨西哥科技大学研究园公司 | 用于药物递送的脂质前药 |
| BR112022019864A2 (pt) * | 2020-03-31 | 2022-11-16 | Nuo Beta Pharmaceutical Tech Shanghai Co Ltd | Composto de oxofenilarsina deuterada e uso do mesmo |
| JP2024537837A (ja) * | 2021-09-30 | 2024-10-16 | ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド | ハロゲン化フェニルアルシンオキシド化合物およびその用途 |
-
2020
- 2020-07-03 TW TW109122503A patent/TW202126294A/zh unknown
- 2020-07-06 KR KR1020227003749A patent/KR20220071175A/ko not_active Ceased
- 2020-07-06 CA CA3149104A patent/CA3149104A1/en active Pending
- 2020-07-06 BR BR112022000155A patent/BR112022000155A2/pt not_active Application Discontinuation
- 2020-07-06 JP JP2022526849A patent/JP2022538505A/ja active Pending
- 2020-07-06 PH PH1/2022/550254A patent/PH12022550254A1/en unknown
- 2020-07-06 CN CN202311755839.1A patent/CN118105372A/zh active Pending
- 2020-07-06 AU AU2020309681A patent/AU2020309681A1/en not_active Abandoned
- 2020-07-06 EP EP20836327.5A patent/EP3995134A4/en active Pending
- 2020-07-06 CN CN202080049288.5A patent/CN114555056B/zh active Active
- 2020-07-06 US US17/624,850 patent/US20230115711A1/en active Pending
- 2020-07-06 WO PCT/CN2020/100377 patent/WO2021004422A1/zh not_active Ceased
- 2020-07-06 MX MX2022000287A patent/MX2022000287A/es unknown
- 2020-07-06 PE PE2022000005A patent/PE20220942A1/es unknown
-
2022
- 2022-01-03 IL IL289586A patent/IL289586A/en unknown
- 2022-02-07 CO CONC2022/0001218A patent/CO2022001218A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020309681A1 (en) | 2022-02-24 |
| KR20220071175A (ko) | 2022-05-31 |
| IL289586A (en) | 2022-03-01 |
| WO2021004422A1 (zh) | 2021-01-14 |
| CA3149104A1 (en) | 2021-01-14 |
| JP2022538505A (ja) | 2022-09-02 |
| EP3995134A4 (en) | 2023-07-12 |
| MX2022000287A (es) | 2022-06-16 |
| US20230115711A1 (en) | 2023-04-13 |
| EP3995134A1 (en) | 2022-05-11 |
| CN118105372A (zh) | 2024-05-31 |
| CN114555056B (zh) | 2024-01-05 |
| TW202126294A (zh) | 2021-07-16 |
| PE20220942A1 (es) | 2022-05-31 |
| PH12022550254A1 (en) | 2023-06-26 |
| CN114555056A (zh) | 2022-05-27 |
| BR112022000155A2 (pt) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| CO2022001218A2 (es) | Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso | |
| CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
| PY2054376A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| CO2026004964A2 (es) | Moduladores de kras | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
| ECSP11005768A (es) | Derivados de azol-pirimidina condensados | |
| CL2021000793A1 (es) | Inhibición de la proteasa 30 específica de la ubiquitina (usp30) | |
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| CO2022008171A2 (es) | Derivado tricíclico de dihidroimidazopirimidona, método de preparación del mismo, composición farmacéutica y uso del mismo | |
| CO2019002555A2 (es) | Composición farmacéutica | |
| CO2024000054A2 (es) | Forma cristalina de tolebrutinib y método de preparación y su uso | |
| CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
| CO2022015428A2 (es) | Compuesto de oxofenilarsina deuterada y uso del mismo | |
| AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos | |
| CL2025002366A1 (es) | Compuesto que contiene trifluorometilsulfonilo. | |
| CL2025000581A1 (es) | Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren | |
| CO2025018537A2 (es) | Formulación que comprende un conjugado anticuerpo-fármaco dirigido a claudina 18.2, método para su preparación y uso | |
| UY38829A (es) | Cannabinoides solubles en agua | |
| MX2021007032A (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos. | |
| PL438696A1 (pl) | Związki stanowiące C20-modyfikowane pochodne salinomycyny, sposób ich otrzymywania, kompozycja je zawierająca, zastosowanie tych związków oraz produkty pośrednie jak i sposoby ich otrzymywania | |
| CO2022009062A2 (es) | Composición para la preparación de alulosa y procedimiento para la preparación de alulosa mediante el uso de la misma |